Literature DB >> 26187349

(68)Ga-PSMA-PET/CT-Guided Salvage Retroperitoneal Lymph Node Dissection for Disease Relapse After Radical Prostatectomy for Prostate Cancer.

Riccardo Schiavina1, Francesco Ceci2, Daniele Romagnoli1, Christian Uprimny3, Eugenio Brunocilla1, Marco Borghesi1, Paolo Castellucci4, Tiziano Graziani4, Stefano Fanti4, Irene Virgolini3.   

Abstract

Entities:  

Keywords:  (68)Ga-PSMA-PET/CT; Biochemical relapse; Hormone sensitive; PSMA; Prostate cancer; S-LND; Salvage lymph node dissection

Mesh：

Substances：

Year:  2015        PMID： 26187349     DOI： 10.1016/j.clgc.2015.06.004

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  9 in total

1.  Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand.

Authors:  Stefano Boschi; Jason T Lee; Seval Beykan; Roger Slavik; Liu Wei; Claudio Spick; Uta Eberlein; Andreas K Buck; Filippo Lodi; Gianfranco Cicoria; Johannes Czernin; Michael Lassmann; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-22       Impact factor: 9.236

Review 2.  PET imaging for lymph node dissection in prostate cancer.

Authors:  Elena Incerti; Paola Mapelli; Luigi Gianolli; Maria Picchio
Journal:  World J Urol       Date:  2016-10-17       Impact factor: 4.226

Review 3.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

Review 4.  PSMA PET and Radionuclide Therapy in Prostate Cancer.

Authors:  Kirsten Bouchelouche; Baris Turkbey; Peter L Choyke
Journal:  Semin Nucl Med       Date:  2016-09-03       Impact factor: 4.446

Review 5.  PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.

Authors:  S P Rowe; M A Gorin; M E Allaf; K J Pienta; P T Tran; M G Pomper; A E Ross; S Y Cho
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-05-03       Impact factor: 5.554

6.  Available active surveillance follow-up protocols for small renal mass: a systematic review.

Authors:  Giacomo Rebez; Nicola Pavan; M Carmen Mir
Journal:  World J Urol       Date:  2021-01-16       Impact factor: 4.226

Review 7.  Current status of theranostics in prostate cancer.

Authors:  Irene Virgolini; Clemens Decristoforo; Alexander Haug; Stefano Fanti; Christian Uprimny
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-12-28       Impact factor: 9.236

8.  Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy.

Authors:  Nina-Sophie Schmidt-Hegemann; Wolfgang Peter Fendler; Harun Ilhan; Annika Herlemann; Alexander Buchner; Christian Stief; Chukwuka Eze; Paul Rogowski; Minglun Li; Peter Bartenstein; Ute Ganswindt; Claus Belka
Journal:  Radiat Oncol       Date:  2018-03-02       Impact factor: 3.481

9.  Enhancing PSMA-uptake with androgen deprivation therapy - a new way to detect prostate cancer metastases?

Authors:  Conrad Leitsmann; Paul Thelen; Marianne Schmid; Johannes Meller; Carsten-Oliver Sahlmann; Birgit Meller; Lutz Trojan; Arne Strauss
Journal:  Int Braz J Urol       Date:  2019 May-Jun       Impact factor: 1.541
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.